

Extracellular Novel RAGE Binding Protein (EN-RAGE) and
Uses Thereof

5 Abstract of the Disclosure

The present invention provides for an isolated human EN-RAGE peptide. The present invention also provides for a method for determining whether a compound is capable of inhibiting
10 the interaction of an EN-RAGE peptide with a RAGE peptide, which comprises: (a) admixing: (i) a RAGE peptide or an sRAGE peptide or a fragment of either thereof, (ii) an EN-RAGE peptide or a fragment thereof, and (iii) the compound;
15 (b) measuring the level of interaction between the peptide of step (a)(i) and the peptide of step (a)(ii), and (c)
20 comparing the amount of interaction measured in step (b) with the amount measured between the peptide of step (a)(i) and the peptide of step (a)(ii) in the absence of the compound, thereby determining whether the compound is
25 capable of inhibiting the interaction of the EN-RAGE peptide with the RAGE peptide, wherein a reduction in the amount of interaction in the presence of the compound indicates that the compound is capable of inhibiting the interaction. The present invention also provides for a method for inhibiting
inflammation in a subject which comprises administering to the subject a compound capable of interfering with the interaction between EN-RAGE peptide and receptor for advanced glycation endproduct (RAGE) in the subject thereby inhibiting inflammation in the subject.